// App-Quantinova.ai

e21092 : Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Marie-Pier Gauthier

Principal Investigators

  • Maryam Karimi

  • Stefan Michiels

  • Lesley Seymour

  • Elisabeth Brambilla

  • Thierry Le Chevalier

  • Jean-Charles Soria

  • Robert Arthur Kratzke

  • Stephen L. Graziano

  • Ramaswamy Govindan

  • Ming-Sound Tsao

  • Frances A. Shepherd

Medical Centers

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Institut Gustave Roussy, Service de Biostatistique et d’Epidémiologie,...

  • Institut Gustave-Roussy, Villejuif, France

  • Queen's University, Kingston, ON, CA

  • INSERM U823-CHU Grenoble, Grenoble, France

  • Gustave Roussy, Villejuif, France

  • University of Minnesota, Edina, MN

  • Regional Oncology Center, Syracuse, NY

  • Washington University School of Medicine, St. Louis, MO

  • Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

  • Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada

Locations

  • Canada

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • tumor-infiltrating lymphocytes

  • Tumor mutational burden

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved